Get the Stockscreener App
1.25
5.93%
0.07
Okyo Pharma Limited stock is traded at $1.25, with a volume of 20,641.
It is up +5.93% in the last 24 hours and down -0.79% over the past month.
See More
Previous Close:
$1.18
Open:
$1.25
24h Volume:
20,641
Relative Volume:
0.12
Market Cap:
$40.05M
Revenue:
-
Net Income/Loss:
$-13.27M
P/E Ratio:
-7.622
EPS:
-0.164
Net Cash Flow:
$-7.70M
1W Performance:
-5.30%
1M Performance:
-0.79%
6M Performance:
+25.00%
1Y Performance:
-13.81%
1-Day Range:
$1.1903
$1.2599
1-Week Range:
$1.17
$1.48
52-Week Range:
$0.8075
$1.74
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.25 | 40.05M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Okyo Pharma Limited Stock (OKYO) Latest News
OKYO Pharma achieves key stability milestone for Urcosimod in clinical development - Proactive Investors
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod - GlobeNewswire
Small cap wrap: OKYO Pharma, Charbone Hydrogen, Hillcrest... - Proactive financial news
OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment - Seeking Alpha
OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain - Ophthalmology Times
Urcosimod shows promise in long-term stability test - Investing.com
OKYO Pharma confirms stability of drug candidate By Investing.com - Investing.com South Africa
OKYO Pharma confirms stability of drug candidate - Investing.com India
Urcosimod shows promise in long-term stability test By Investing.com - Investing.com Australia
OKYO Pharma Achieves Key Stability Milestone for Urcosimod - TipRanks
Clinical Trial Breakthrough: New Stability Data Strengthens Urcosimod's Path to FDA Approval - Stock Titan
OKYO Pharma reports long-term shelf stability of corneal pain treatment - Proactive financial news
Dauntless Investment Group, LLC Acquires Significant Stake in OK - GuruFocus
OKYO Pharma (NASDAQ:OKYO) versus IN8bio (NASDAQ:INAB) Head-To-Head Analysis - Defense World
OKYO Pharma Limited (NASDAQ:OKYO) Sees Significant Growth in Short Interest - Defense World
Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS - MarketScreener
OKYO Pharma seeks FDA fast track for eye pain treatment By Investing.com - Investing.com Australia
OKYO Pharma seeks FDA Fast Track for eye pain drug By Investing.com - Investing.com Australia
OKYO Pharma seeks FDA fast track for eye pain treatment - Investing.com India
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment - Proactive Investors
OKYO Pharma Seeks FDA Fast Track for Urcosimod in Treating Neuropathic Corneal Pain - TipRanks
OKYO Pharma seeks FDA Fast Track for eye pain drug - Investing.com
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewswire
OKYO Pharma secures $1.4 million non-dilutive funding - MSN
Comparing Immunovant (NASDAQ:IMVT) & OKYO Pharma (NASDAQ:OKYO) - Defense World
OKYO Pharma advances neuropathic corneal pain drug trial - MSN
OKYO Pharma (NASDAQ:OKYO) Receives “Buy” Rating from HC Wainwright - Defense World
H.C. WAINWRIGHT MAINTAINS BUY RATING ON OKYO PHARMA STOCK By Investing.com - Investing.com Australia
H.C. WAINWRIGHT MAINTAINS BUY RATING ON OKYO PHARMA STOCK - Investing.com India
Contrasting OKYO Pharma (NASDAQ:OKYO) and CG Oncology (NASDAQ:CGON) - Defense World
Buy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market Potential - TipRanks
Okyo Pharma's OK-101 renamed urcosimod for eye pain - MSN
H.C. Wainwright maintains Buy on OKYO Pharma with $7 target - MSN
OKYO Pharma’s lead asset receives USAN designation "urcosimod By Investing.com - Investing.com Nigeria
OKYO Pharma's lead asset receives USAN designation "urcosimod - MSN
OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors UK
Okyo Pharma's OK-101 renamed urcosimod for eye pain By Investing.com - Investing.com South Africa
OKYO Pharma's lead asset receives USAN designation "urcosimod By Investing.com - Investing.com UK
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod - GlobeNewswire
OKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod - TipRanks
Okyo Pharma Limited Announces OK-101 Officially Assigned USAN : Urcosimod -February 12, 2025 at 07:01 am EST - Marketscreener.com
Revolutionary Eye Drug Urcosimod Targets Two Major Unmet Medical Needs - StockTitan
OKYO Pharma says OK-101 gains USAN reflecting role in ocular disease modulation - Proactive Investors USA
H.C. Wainwright maintains Buy on OKYO Pharma with $7 target By Investing.com - Investing.com South Africa
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):